Compare Intel Corp (INTC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs TG Therapeutics Inc — how do they compare? Intel Corp trades at $102.5 (market cap $487.82B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Intel Corp is far larger — about 59.1× TG Therapeutics Inc's market cap, and Intel Corp pays a 2.24% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| INTC | TGTX | |
|---|---|---|
Market Cap | $487.82B | $8.26B |
Volume | 43,552,012 | — |
Sector | Technology | Health |
52-Week High | $140.94 | $59.06 |
52-Week Low | $19.31 | $26.39 |
Enterprise Value | $500.07B | $8.50B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $97.87, up 2.97% on the day, with technical indicators showing a bullish overall signal despite mixed moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$267 million in 2025. Recent news highlights volatility in semiconductor stocks amid AI-driven market shifts, with Intel expanding its Google Cloud AI partnership to boost enterprise growth.
Intel's outlook is cautiously optimistic, supported by earnings beats and strategic AI initiatives, but risks include intense competition, margin pressures, and sector volatility. The consensus price target of $109.55 suggests potential upside, though investors must weigh financial recovery against technological challenges in a dynamic chip market.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
